Vera Therapeutics Inc (NASDAQ: VERA)’s stock price has gone decline by -5.81 in comparison to its previous close of 44.94, however, the company has experienced a -2.69% decrease in its stock price over the last five trading days. The Motley Fool reported 2024-04-13 that Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors as Vera Therapeutics’ candidate.
Is It Worth Investing in Vera Therapeutics Inc (NASDAQ: VERA) Right Now?
The 36-month beta value for VERA is at 1.12. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VERA is 40.94M, and currently, shorts hold a 15.42% of that float. The average trading volume for VERA on May 10, 2024 was 1.05M shares.
VERA’s Market Performance
VERA’s stock has seen a -2.69% decrease for the week, with a 1.71% rise in the past month and a 12.70% gain in the past quarter. The volatility ratio for the week is 7.67%, and the volatility levels for the past 30 days are at 7.89% for Vera Therapeutics Inc The simple moving average for the last 20 days is 0.08% for VERA’s stock, with a simple moving average of 70.35% for the last 200 days.
Analysts’ Opinion of VERA
Many brokerage firms have already submitted their reports for VERA stocks, with Oppenheimer repeating the rating for VERA by listing it as a “Outperform.” The predicted price for VERA in the upcoming period, according to Oppenheimer is $26 based on the research report published on January 25, 2024 of the current year 2024.
Raymond James gave a rating of “Outperform” to VERA, setting the target price at $29 in the report published on December 18th of the previous year.
VERA Trading at -0.74% from the 50-Day Moving Average
After a stumble in the market that brought VERA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.64% of loss for the given period.
Volatility was left at 7.89%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares sank -13.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.86% lower at present.
During the last 5 trading sessions, VERA fell by -2.69%, which changed the moving average for the period of 200-days by +168.08% in comparison to the 20-day moving average, which settled at $41.97. In addition, Vera Therapeutics Inc saw 175.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERA starting from Young Joseph R, who sale 5,714 shares at the price of $40.00 back on Apr 10 ’24. After this action, Young Joseph R now owns 53,171 shares of Vera Therapeutics Inc, valued at $228,560 using the latest closing price.
Grant Sean, the CHIEF FINANCIAL OFFICER of Vera Therapeutics Inc, sale 99,828 shares at $39.61 during a trade that took place back on Apr 03 ’24, which means that Grant Sean is holding 66,337 shares at $3,954,516 based on the most recent closing price.
Stock Fundamentals for VERA
The total capital return value is set at -0.67. Equity return is now at value -107.50, with -62.54 for asset returns.
Based on Vera Therapeutics Inc (VERA), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.76. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -53.66.
Currently, EBITDA for the company is -103.87 million with net debt to EBITDA at -0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.42.
Conclusion
In conclusion, Vera Therapeutics Inc (VERA) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
